Using a population-based analysis to determine the management and treatment of early-stage small-cell lung cancer Editorial Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Carcinoma, Small Cell
  • Cranial Irradiation
  • Lung Neoplasms
  • Pneumonectomy
  • Secondary Prevention

abstract

  • ©2016 American Society of Clinical Oncology. Decades of randomized clinical trials have led to the development of a clear treatment approach for patients with limited-stage or extensive-stage small-cell lung cancer (SCLC). The standard first-line chemotherapy regimen is cisplatin or carboplatin plus etoposide, with the addition of radiation therapy for patients with limited-stage SCLC whose cancer is confined to the chest in a single tolerable radiation field. Patients with limited- And extensive-stage SCLC who demonstrate a response to first-line platinum-based therapy generally are offered prophylactic cranial irradiation (PCI), which has been shown to decrease the risk of intracranial recurrence and improve overall survival.

publication date

  • April 2016

Research

keywords

  • Editorial

Identity

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.6462

PubMed ID

  • 26884572

Additional Document Info

start page

  • 1027

end page

  • 9

volume

  • 34

number

  • 10